Acceptance and preference for long-acting antiretrovirals among people living with HIV in China
This study reveals a high acceptance of LAARV among PLHIV in China and identifies key potential user groups, thereby addressing a critical evidence gap regarding LAARV implementation in the country. A cost-competitive long-acting intramuscular injection ART is the most preferred LAARV option in China.
Authors
- Hong Shang
- Haibo Ding (ORCID: https://orcid.org/0000-0002-9445-5473)
- Wenqing Geng (ORCID: https://orcid.org/0000-0002-7008-9974)
- Qi Wang (ORCID: https://orcid.org/0000-0003-1208-6211)
- Xiaolin Li (ORCID: https://orcid.org/0000-0003-1524-051X)
- Jing Liu (ORCID: https://orcid.org/0000-0001-5207-7614)
- Jing Kang (ORCID: https://orcid.org/0009-0009-2874-3678)
- Yongjun Jiang (ORCID: https://orcid.org/0000-0002-0589-9807)
Institutions
- Liaoning University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- First Hospital of China Medical University (CN)
- South China Institute of Collaborative Innovation (CN)
- China Medical University (CN)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1186/s12889-025-25585-w
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00